Andrew Blauvelt, David M Pariser, Stephen Tyring, Jerry Bagel, Andrew F Alexis, Jennifer Soung, April W Armstrong, Elisa Muscianisi, Farid Kianifard, Jennifer Steadman, Rajendra Prasad Sarkar, Sandra Garcet, James G Krueger
BACKGROUND: The IL-17A inhibitor secukinumab has demonstrated consistent efficacy and safety in patients with moderate-to-severe plaque psoriasis, with normalization of molecular and histopathologic psoriasis markers. OBJECTIVE: To investigate treatment effects of secukinumab on clinical signs and psoriatic inflammation markers over 52 weeks in patients with psoriasis. METHODS: In the ObePso-S study (NCT03055494), patients with psoriasis were randomized 2:1 to receive secukinumab 300 mg (n = 54) or placebo (n = 28), stratified by body weight (<90 or ≥90 kg), for 52 weeks...
January 9, 2023: Journal of Dermatological Science